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We have developed an efficient method to target lentivirus-
mediated gene transduction to a desired cell type. It involves
incorporation of antibody and fusogenic protein as two distinct
molecules into the lentiviral surface. The fusogen is constructed by
modifying viral envelope proteins, so that they lack the ability to
bind to their cognate receptor but still retain the ability to trigger
pH-dependent membrane fusion. Thus, the specificity of such a
lentiviral vector is solely determined by the antibody, which is
chosen to recognize a specific surface antigen of the desired cell
type. This specific binding then induces endocytosis of the surface
antigen, bringing the lentivirus into an endosome. There, the
fusogen responds to the low pH environment and mediates mem-
brane fusion, allowing the virus core to enter the cytosol. Using
CD20 as a target antigen for human B cells, we have demonstrated
that this targeting strategy is effective both in vitro and in intact
animals. This methodology is flexible and can be extended to other
forms of cell type-specific recognition to mediate targeting. The
only requirement is that the antibody (or other binding protein)
must be endocytosed after interaction with its cell surface-binding
determinant.
antibody  gene therapy  lentivirus  retrovirus  targeted gene delivery
Gene therapy is the introduction of a functional gene into atarget cell to provide a therapeutic advantage (1). A particu-
larly desirable gene therapy protocol would be to precisely deliver
a gene of interest to specific cells or organs in vivo by means of
administration of a designed gene delivery vehicle. Certain viruses
are natural gene delivery systems, andmuch effort has been focused
on engineering viral vectors as gene transfer vehicles (1, 2). Among
these vectors, ones derived from oncoretroviruses and lentiviruses
exhibit promising features because they have the ability to produce
stable transduction, maintain long-term transgene expression and,
for lentiviruses, to transduce nondividing cells. Targeting such
viruses to particular cell types has proved to be challenging. We
report here a general methodology that allows such targeting, even
in vivo, and that is remarkably flexible.
Many attempts have been made to develop targetable transduc-
tion systems by using retroviral and lentiviral vectors (3, 4). Signif-
icant effort has been devoted to altering the envelope glycoprotein
(Env), the protein that is responsible for binding the virus to cell
surface receptors and for mediating entry. The plasticity of the
surface domain of Env allows insertion of ligands, peptides and
single-chain antibodies (5–14) that can direct the vectors to specific
cell types. However, this manipulation adversely affects the fusion
domain of Env, resulting in low viral titers. The unknown and
delicate coupling mechanisms of binding and fusion make it ex-
tremely difficult to reconstitute fusion function once the surface
domain of the same molecule has been altered (4). Another
approach involves using a ligand protein or antibody as a bridge to
attach the virus to specific cells (15–18). The challenge to this
approach is that the Env, once complexed with the one end of the
bridge molecule, fuses inefficiently. Because no practical strategies
are available for targeted in vivo gene delivery, current gene therapy
clinical trials are based on in vitro transduction of purified cells
followed by infusion of the modified cells into the patient. This is
an expensive procedure, with significant safety challenges.
Our strategy involves uncoupling the target cell recognition
function from the fusion function by providing them in separate
proteins. For recognition, we use antibodies, and, for fusion, we use
a viral glycoprotein that has been mutated to inactivate its binding
ability. We make lentiviral vectors that incorporate both molecules
into their surface. Our working hypothesis was that the antibody
should recognize a molecular constituent on the target cell mem-
brane and attach the lentivirus to the cell surface (Fig. 5, which is
published as supporting information on the PNAS web site).
Antibody binding should then induce endocytosis, bringing the
lentivirus into an endosome. There, the fusogenic molecule (FM)
should respond to the low pH environment and trigger membrane
fusion, allowing the virus core to enter the cytosol. After reverse
transcription and migration of the product to the nucleus, the
genome of the vector should integrate into the target cell genome,
incorporating the vector’s transgene into the cell’s inheritance.
Results
Construction of pH-Dependent Fusogen. Effective FMs for the pro-
posed system should be able to incorporate into the lentivirus
envelope and induce membrane fusion at low pH, independent of
receptor binding. There are two classes of such FMs (19). The class
I fusogens trigger membrane fusion using helical coiled-coil struc-
tures whereas the class II fusogens trigger fusion with  barrels.
These two structures have different mechanics and kinetics (19),
and bothwere evaluated to determinewhichwould be better for the
promotion of infection. One class I fusogen, HA from influenza
Afowl plague virusRostock34 (FPV), was previously found to
pseudotype murine leukemia virus (MLV) (20). Cannon and
coworkers (21) created a binding defective version of FPV HA
designated as HAmu (Fig. 1A). When incorporated into MLV
displaying a functionally attenuated envelope glycoprotein, HAmu
could enhance viral transduction efficiency (21). HAmu-mediated
fusion is thought to be independent of receptor binding (3). The
class II FM that we tested was the Sindbis virus glycoprotein from
the alphavirus family (22) and is designated as SIN. SIN consists of
two transmembrane proteins (23), one responsible for fusion (E1)
and the other for cell binding (E2). SIN is known to pseudotype
both oncoretroviruses and lentiviruses. By inserting the IgG-
binding domain of protein A (ZZ domain) into the E2 protein and
making several additional mutations to inactivate the receptor-
binding sites, Chen and coworkers (16) made a binding-deficient
and fusion-competent SIN. We adapted this form of SIN but
replaced the ZZ domain with a 10-residue tag sequence, for which
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there exists a monoclonal antibody that allows monitoring of SIN
expression; we designated it SINmu (Fig. 1C).
Construction of Membrane-Bound Antibody for Targeting. The anti-
body that we have chosen for targeting in this study is the anti-
human CD20 antibody (CD20), a version of which is currently
being used in the treatment of B cell lymphomas. We generated a
construct that encodes a mousehuman chimeric anti-CD20 anti-
body with the human membrane-bound IgG constant region
(pCD20). Genes encoding human Ig and Ig, the two associated
proteins that are required for surface expression of antibodies, were
cloned into a construct designated pIg.
Preparation of Recombinant Lentiviral Vectors. The production of
lentiviruses enveloped with both anti-CD20 antibody and the
candidate FMwas achieved by cotransfection of 293T cells with the
lentiviral vector FUGW, plasmids encoding viral gag, pol, and rev
genes, pCD20, pIg and pFM (the plasmid encoding a FM,
either HAmu or SINmu), by using a standard calcium phosphate
precipitation method (24). FUGW is a self-inactivating and repli-
cation-incompetent lentiviral vector that carries the human ubiq-
uitin-C promoter driving a GFP reporter gene (25). As a control,
the Env derived from vesicular stomatitis virus (VSVG) was used
as a joint recognition and fusion protein. FACS analysis of the
transfected cells showed that virtually all expressed some level of
GFP as an indicator of the presence of the viral vector (Figs. 1B and
DUpper). Some 30%ofGFP-positive cells coexpressedHAmu and
CD20 on the cell surface (Fig. 1B Lower). A slightly smaller
percentage (20%) of the 293T cells exhibited coexpression of
GFP, SINmu, and CD20 (Fig. 1D). The resultant viruses from
these transfected production cells were designated FUGW
CD20HAmu and FUGWCD20SINmu.
Coincorporation of Fusogen and Antibody into Lentiviral Vectors. To
examine whether CD20 and the FM were incorporated in the
same virion, we performed a virus–cell binding assay. As a target,
wemade a 293T cell line stably expressing theCD20 protein antigen
(293TCD20; Fig. 2A). The parental cell line 293T served as a
negative control. The viral supernatants were incubated with the
target cells at 4°C for half an hour. The resultant binding was
assayed by means of a three-staining scheme (Fig. 2B). FACS
analysis showed that lentivectors bearing CD20 were in fact able
to bind to CD20-expressing 293T cells (Fig. 2CUpper). The control
of 293T cells with no CD20 expression displayed no detectable
CD20, showing that the virus binding to cells must be due to a
specific interaction between the cell surface CD20 antigen and the
viral surfaceCD20molecule. In another control, the virus bearing
only FM exhibited no ability to bind either cell line, indicating that
the HAmu and SINmu did lack the capacity for cell binding (L.Y.,
L.B., D.B., and P.W., unpublished work). FACS analysis also
showed that the virus bound to the 293TCD20 cell surface
displayed theFMs (Fig. 2CLower), suggesting that bothCD20 and
FM were incorporated on the same virion, which was further
confirmed by FACS plots of CD20 versus FM (Fig. 2D). In
addition to codisplay, these results suggest that the presence of the
FM does not affect the CD20 binding to CD20.
Targeted Transduction of Lentiviral Vectors to Cell Line in Vitro. We
next examined whether CD20-bearing virus can transfer genes
into cells expressing CD20 in a cell-specific manner. GFP
expression was used to measure the transduction efficiency. The
Fig. 1. Coexpression of antibody and fusogenic protein on the surface of the virus packaging cell line. (A) The class I fusion protein HAmu derived from influenza
A (FPV) HA. HA contains two glycoproteins after maturation: HA1 for binding to cell surface receptor, sialic acid; HA2 for triggering membrane fusion. Three
point mutations within the receptor binding sites (a1, Y106F; a2, E199Q; a3, G237K) (21) were introduced to generate the binding-defective but fusion-competent
HAmu. Single letter amino acid abbreviations are as follows: A, alanine; D, aspartic acid; E, glutamic acid; F, phenylalanine; G, glycine; K, lysine; M, methionine;
P, proline; Q, glutamine; V, valine; Y, tyrosine. (B) FACS analysis of virus-producing cells. 293T cells were transiently transfected with plasmids encoding the
following: the lentiviral vector FUGW; the membrane-bound antibody CD20; the accessory proteins for antibodies, Ig and Ig; the fusion protein HAmu; and
viral gag, pol, and rev genes. Expression of CD20 and HAmu was detected by using anti-human IgG antibody and anti-FPV HA antibody. (C) The class II fusion
protein SINmu derived from SIN. SIN contains two membrane glycoproteins (E1 and E2) and a signal peptide (E3): E1 for mediating fusion, E2 for receptor binding,
and E3 as a signal sequence for processing of E2 glycoprotein. A 10-residue tag sequence (MYPYDVPDYA) was inserted between amino acids 71 and 74 of the
E2 glycoprotein. A series of alterations (a4: deletion of amino acids 61–64 of E3; a5: mutations of 68SLKQ71 into 68AAAA71; mutations of 157KE158 into
157AA158) (16) was introduced to yield the binding-defective and fusion-competent SINmu. (D) Directly analogous to B, except that SINmu was used for the
fusion protein and was detected by an anti-tag antibody.
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supernatants containing lentivectors bearing various surface
proteins were incubated with CD20-expressing target cells, and
293T cells served as a control. Four days posttransduction, the
efficiency of targeting was analyzed by FACS. Fig. 3A (rightmost
image) shows that FUGWCD20HAmu viral particles could
specifically transduce 16% of 293TCD20 cells. Images to the
left show that transduction required the presence on the virions
of HAmu, but there was some background transduction with
virions lacking CD20, likely because of residual weak binding
of HAmu to its ligand, sialic acid. The titer for FUGW
CD20HAmu (fresh viral supernatant, no concentration) was
estimated to be 1  105 transduction units (TU)ml; the titer
was determined by the percentage of GFP cells in the dilution
ranges that showed a linear response. The 293T cells showed a
small background infection level but no specific transduction by
FUGWCD20HAmu (Fig. 3A Lower). When SINmu was
used as the fusion protein, substantial enhancement of specific
transduction was observed (52%; Fig. 3B). The titer for FUGW
CD20SINmu was estimated to be1 106 TUml. Also, we
detected a much lower transduction in the absence of the binding
protein (1%). Thus, the data in Fig. 3B show that SINmu is a
better fusion protein to partner with CD20 for targeting
lentiviral vectors. When we monitored the transduction at
various time points using FACS, we found that SINmu-
containing virions exhibited faster transduction kinetics than
those with HAmu (L.Y., L.B., D.B., and P.W., unpublished
work). Both FUGWCD20HAmu and FUGW
CD20SINmu could be concentrated by ultracentrifugation
with a 90% recovery rate, which is important for in vivo
application.
To assess whether CD20 and the fusion protein (HAmu or
SINmu) had to be incorporated into the same viral particle, and
therefore functioned in cis to mediate transduction, we mixed
FUGWCD20 with FUGWHAmu or FUGWSINmu, each
displaying only one protein, and tested their transduction of 293T
CD20 cells. This procedure did not result in specific transduction,
indicating that the specific transduction conferred by the engi-
neered recombinant viruses requires the two proteins to be dis-
played on the same viral particle.
Antibody–Antigen Interaction Responsible for Targeted Transduction.
It seems that two distinct proteins can carry the binding and fusion
events of engineered lentiviruses for targeted transduction. To
further confirm that the specificity we observed was a consequence
of interaction between CD20 and CD20, we transduced 293T
CD20 cells in the presence of anti-CD20 blocking antibody. As
expected, a dramatic decrease of infectivity was detected for both
FUGWCD20HAmu (L.Y., L.B., D.B., and P.W., unpublished
work) and FUGWCD20SINmu (Fig. 3D), suggesting the
essential role of antibody–antigen binding for the targeted
transduction.
Confirmation of pH Dependence of Fusogen.To examine the require-
ment for a low pH comparment to allow the recombinant lentivec-
tors to penetrate into cells, we incubated both FUGW
CD20HAmu and FUGWCD20SINmu with 293TCD20
cells in the absence or presence of ammonium chloride (NH4Cl),
which can neutralize acidic endosomal compartments. Addition of
NH4Cl to cells completely abolished transduction by either
FUGWCD20HAmu (L.Y., L.B., D.B., and P.W., unpublished
work) or FUGWCD20SINmu (Fig. 3E). These results are
consistent with the low pH requirement of HA and SIN to trigger
membrane fusion. More direct evidence for pH-dependent fusion
was provided by a cell–cell fusion assay. 293T cells expressing GFP,
Fig. 2. Virus–cell binding assay to study the codisplay of antibody and fusogenic protein on the lentiviral surface. (A) FACS analysis of target cell line 293TCD20.
CD20 expression was detected by using anti-CD20 antibody. Solid line, expression of CD20 in 293TCD20; shaded area, CD20 expression in 293T cells (as a control).
(B) Schematic representation of three-staining scheme used for analyzing virus–cell binding assay. Three stainings were used to detect the presence of CD20,
CD20, and the fusogenic molecule (HAmu or SINmu), respectively. (C Left) FACS plots of 293TCD20 cells incubated with FUGWCD20HAmu. The binding
of virus to 293TCD20 cells was probed with antibody against CD20 (anti-IgG) and HAmu. Solid line, analysis on 293TCD20; shaded area, analysis on 293T (as
a control). (C Right) FACS plots of 293TCD20 cells incubated with FUGWaCD20SINmu. The binding of virus to 293TCD20 cells was detected by antibody
against CD20 and SINmu. Solid line, analysis on 293TCD20; shaded area, analysis on 293T (as a control). (D) Codisplay of antibody and fusogenic protein was
analyzed by a density plot correlating the presence of the two proteins.
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surface CD20, and FM were incubated with 293TCD20 cells in
a low-pH buffer for half an hour, followed by culturing in regular
medium. Both HAmu and SINmu induced cell–cell fusion by
forming multinucleated polykaryons (Fig. 3C). The interaction
betweenCD20 andCD20dramatically enhances the probability of
fusion, because a similar experiment with cells that lacked CD20
and CD20 yielded a much lower level of fusion (L. Y., L.B., D.B.,
and P.W., unpublished work). The CD20CD20 interaction prob-
ably brings the cell membranes into close apposition, facilitating the
action of the fusion protein.
Targeted Transduction of Lentiviral Vectors to Primary B Cells.Having
established the ability of the system to mediate CD20-specific
transduction of artificially created cell lines, we next investigated the
possibility of specific transduction of primary human B-lymphoid
cells, cells that naturally carry the CD20 antigen. Fresh, unfrac-
tionated human peripheral bloodmononuclear cells (PBMCs)were
transducedwith FUGWCD20SINmu and then stimulatedwith
LPS to expand the B cell population. Four days later, the cells were
stained for CD19 (a B cell marker), CD20, and GFP expression
(Fig. 4A). We found that35% of cells were CD20 B cells under
our culture condition. When we gated on CD20 B cells, the
majority of them were GFP. On the contrary, virtually no GFP
cells were detected when we gated on CD20 non-B cells, con-
firming that the transduction was strictly dependent on CD20
expression. In another control experiment, fresh PBMCs were
transduced with FUGWCD20SINmu followed by stimulation
with phorbol 12-myristate 13-acetate (PMA) and ionomycin to
expandT cells. FACS analysis of these T cells showed no expression
of GFP (Fig. 6, which is published as supporting information on the
PNAS web site), confirming transduction specificity.
To demonstrate that the targeting method is not limited to the
lentiviral vector FUGW, we evaluated two additional lentiviral
vectors with different promoter configurations. Kohn and co-
workers (26) have incorporated the Ig heavy chain enhancer
(E) with associated matrix attachment regions into lentivectors
carrying either the human cytomegalovirus (CMV) promoter
(CCMV) or the murine phosphoglycerate kinase promoter
(CPGK).We adapted these two lentiviral vectors into our system
and prepared recombinant lentiviruses CCMVCD20SINmu
and CPGKCD20SINmu. Transduction of PBMC-derived B
cells with these viral supernatants exhibited results similar to
those observed previously with FUGW (Fig. 4A).
Targeted Transduction of Recombinant Lentiviral Vectors in Vivo.The
real test of this system is whether it will mediate specific transduc-
tion in vivo. For this purpose, we used a human PBMC xenograft
in a mouse model. Fresh human PBMCs (100  106 per mouse)
were transferred into irradiated immunodeficient RAG2/c/
mice through a tail vein injection. Engineered lentiviruses bearing
CD20 and SINmu were administered through the tail vein 6 h
after human cell transfer.After 2 days, we collected thewhole blood
from these mice, and the cells were analyzed for surface antigens
andGFP expression. Approximately 30–40%of the cells recovered
from the mice were human T cells (CD3), and 0.1–0.3% were
CD20 human B cells (Fig. 4B). Three populations were analyzed
forGFP expression: CD20, CD3, andCD20CD3. None of the
cells harvested from mice injected with virus bearing a control
antibody and SINmu (FUGWb12SINmu) showed evidence of
GFP expression in any of the three populations (Fig. 4B). In
contrast, GFP expression was observed in at least 40% of the
CD20 cells isolated from mice injected with FUGW
CD20SINmuwhereas no transduction was detected in the other
two populations.
Discussion
This demonstration of targeting efficient gene delivery vehicles
strictly to the desired cell types in vivo greatly enhances the
Fig. 3. Targeting of lentivectors bearing both antibody and fusion protein to
293TCD20 cells in vitro. (A) 293TCD20 cells (2 105) were transduced with 500
l of fresh unconcentrated FUGWCD20 (no HAmu), FUGWHAmu (noCD20),
or FUGWCD20HAmu. 293T cells (no expression of CD20) were included as
controls. The resulting GFP expression was analyzed by FACS. The specific trans-
duction titer for FUGWCD20HAmu was estimated to be1 105 TUml. (B)
A similar transduction experiment was performed by using unconcentrated
FUGWSINmu (noCD20) or FUGWCD20SINmu. For comparison of targeting
specificity, cells were also transduced with FUGWHAmu. The specific transduc-
tion titer for FUGWCD20SINmu was estimated to be 1  106 TUml. (C)
Evidence of pH-dependent fusion of HAmu and SINmu by a cell–cell fusion assay.
293T cells (0.1  106) transiently transfected to express GFP and surface CD20
and fusion protein (either HAmu or SINmu), and 293TCD20 cells were mixed
together,washedoncewithnormalPBS(pH7.4),andincubatedin lowpHPBS(pH
5.0) or normal pH PBS (as a control) for half an hour at 37°C. The cells were then
washed and cultured in the regular medium for 1 day. Cells were visualized by
epifluorescence microscope equipped with a GFP filter set. (D and E) Effect of
addition of soluble CD20 (D) or NH4Cl (E). CD20 or NH4Cl was added into viral
supernatants during transduction for 8 h. Then, the supernatants were replaced
with fresh medium. The cells were analyzed for GFP expression after 2 days.
Isotype-matched antibody was used as a control for D.
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therapeutic potential of lentivirus-mediated gene therapy and
alleviates concerns of off-target effects. Possibly themost important
implication of the work is that gene therapy could now be carried
out as an inexpensive procedure, able to be considered even in the
less-developed world.
In our approach, we break up the binding and fusion
functions into two separate molecules that are inserted into the
viral envelope. This methodology is particularly easy with
lentiviruses (or other retroviruses) because these viruses
readily incorporate into their envelope whatever proteins are
found on the surface of producing cells (27). Other viruses
have surfaces with many close-packed viral glycoproteins and
exclude cellular proteins. A major advantage of this scheme
over others where the viral protein is engineered with a foreign
binding component is that the fusion protein maintains its full
biological activity so that viral titer is not killed for increased
specificity. The other key to the method is choosing a viral
glycoprotein that mediates fusion in response to low pH and
a cellular receptor that is efficiently endocytosed after anti-
body binding. The fusion molecule must exhibit fast enough
kinetics that the viral contents can empty into the cytosol
before the degradation of the viral particle. Our choice of
CD20 as a target was arbitrary. We have already extended the
method to other antibodies and cell surface receptor–ligand
pairs.§ We envision that the f lexibility (easy combination of
antibody, or other binding protein, and fusiogenic molecule)
and broadness (availability of monoclonal antibodies or li-
gands for many endocytosed cell-specific surface molecules) of
this method will facilitate the application of targeted gene
delivery for therapy and research.
Materials and Methods
Construct Preparation. The cDNAs of the human  light chain
constant region and the membrane bound human IgG1 constant
region were amplified and inserted downstream of human CMV
and EF1promoters, respectively, in the pBudCE4.1 vector (In-
vitrogen). We cloned the light and heavy chain variable regions
from the murine anti-CD20 antibody (clone 2H7) using PCR
amplification and inserted them directly upstream of the corre-
sponding constant regions. The resulting construct was designated
pCD20. We cloned cDNAs of human Ig and Ig into the
pBudCE4.1 vector (Invitrogen) to yield pIg.
P. Cannon (University of Southern California and Childrens
Hospital, Los Angeles) was kind enough to provide us with the
construct encoding HAmu (21). We obtained the cDNA for
wild-type SIN from J. Strauss’s laboratory at theCalifornia Institute
of Technology. PCR mutagenesis and assembly were used to
generate the mutant SIN as described by Chen and colleagues (16),
except a 10-residue tag sequence (MYPYDVPDYA) replaced the
ZZ domain of protein A, which is located between amino acids 71
and 74 of the E2 glycoprotein of SIN. This version of SIN is
designated SINmu.
Virus Production. Lentivectors were generated by transfecting 293T
cells by using a standard calcium phosphate precipitation technique
§We have observed that this method can be exploited to target dendritic cells using a
membrane-bound monoclonal antibody against the DEC-205 receptor. In addition, we
found that incorporation of a membrane-bound form of stem cell factor could target
c-kit-positive cells.
Fig. 4. Targeting CD20 human primary B cells in vitro and
in vivo using engineered lentivectors. (A) Fresh, unfraction-
ated human PBMCs (2 106) were transduced by coculturing
with concentrated FUGWCD20SINmu, CCMV
CD20SINmu, or CPGKCD20SINmu (10 106 TU). LPS (50
gml) was added into the culture media for B cells to survive
and grow. After 2 days, the B cell population was identified by
costaining of CD19 and CD20. Solid line, analysis on trans-
duced cells; shaded area, analysis on cells without transduc-
tion (as a control). (B) Fresh human PBMCs were transferred
into irradiated RAG2/c/ mice (100  106 per mouse) via
tail vein injection. Six hours later, concentrated virus (100 
106 TU per mouse) was injected through the tail vein. Two days
later, whole blood was collected from these mice via heart
puncture, and the cells were stained for human CD3 and CD20
and then analyzed by FACS for GFP expression. Shaded area,
no virus treatment; dashed line, treated with FUGW
b12SINmu; solid line, treated with FUGWCD20SINmu.
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(24). 293T cells (80% confluent) in 6-cm culture dishes were
transfected with the appropriate lentiviral vector plasmid (5 g),
together with 2.5 g each of pCD20, pIg, and the packaging
vector plasmids (pMDLgpRRE and pRSV-Rev) (28). The viral
supernatants were harvested 48 and 72 h after transfection and
filtered through a 0.45-m pore size filter.
To prepare high-titer lentivectors, the viral supernatants were
concentrated by using ultracentrifugation (Optima L-80 K pre-
parative ultracentrifuge, Beckman Coulter) for 90 min at
50,000  g. Particles were then resuspended in an appropriate
volume of cold PBS.
Cell Line Construction. The 293TCD20 cell line was generated by
stable transduction via vesicular stomatitis virus (VSVG)-
pseudotyped lentivector. The cDNA of human CD20 was cloned
downstream of the human ubiquitin-C promoter in the lentivector
plasmid FUWto generate FUW-CD20. The lentiviral vector FUW-
CD20was then pseudotypedwithVSVGandwas used to transduce
293T. The resulting cells were subjected to cell sorting to obtain a
uniform population of CD20 cells designated 293TCD20.
Virus–Cell Binding Assay. Cells (293TCD20 or 293T, 0.1  106)
were incubated with 500 l of viral supernatant at 4°C for half an
hour and washed with 4ml of cold PBS. The cells were then stained
with the following three antibodies: an anti-human IgG antibody
(BD PharMingen) to stain CD20, an anti-human CD20 antibody
(BD PharMingen) to stain CD20, and an anti-FPV HA polyclonal
antibody (obtained from H.-D. Klenk, Institute of Virology,
Philipps University, Marburg, Germany) to stain HAmu, or an
anti-tag antibody (Roche Applied Science, Mannheim, Germany)
to stain SINmu. After staining, cells were analyzed by FACS
analysis.
Targeted Transduction of 293TCD20 Cells in Vitro. 293TCD20 cells
(0.2  106 per well) or 293T cells (0.2  106 per well) were plated
in a 24-well culture dish and spin-infected with viral supernatants
(0.5 ml per well) at 2,500 rpm, 30°C for 90 min by using a Beckman
Allegra 6R centrifuge. Then, the medium was removed and re-
placedwith freshmediumand incubated for a further 3 days at 37°C
with 5% CO2. The percentage of GFP cells was determined by
FACS. The transduction titer was measured in dilution ranges that
exhibited a linear response.
Effects of Soluble Antibody and NH4Cl on Viral Transduction. 293T
CD20 cells (0.2  106) and 0.5 ml of viral supernatants were
incubated for 8 h in the absence or presence of graded amounts of
CD20 (BD PharMingen) or NH4Cl. The medium was replaced
with fresh medium and incubated for another 2 days at 37°C with
5% CO2. FACS analysis was used to quantify transduction
efficiency.
Cell–Cell Fusion Assay. 293T cells (0.1 106), transiently transfected
to express GFP, surface CD20, and fusion protein (either HAmu
or SINmu), and 293TCD20 cells (0.1 106) were mixed together,
washed twice with normal PBS (pH 7.4), and incubated in 150 l
of low pH PBS (pH 5.0) or normal pH PBS (pH 7.4) (as a control)
for half an hour at 37°C with 5% CO2. The cells were then washed
extensively and cultured in the regularmedium for 1 day. Cells were
visualized by an epifluorescence microscope equipped with a GFP
filter set.
Targeted Transduction of Primary Human B Cells in Vitro. Fresh,
unfractionated human PBMCs (2 106) (AllCells) were incubated
with concentrated virus with total TUs of 10  106 (based on the
titer on 293TCD20 cells). LPS (50 gml) was then added for B
cells to survive and grow. After 2 days, cells were harvested and
washed in PBS. B cell population was determined by FACS staining
using anti-human CD20 and CD19 antibodies. Targeting transduc-
tion was quantified by gating on the different populations of cells
and measuring their GFP expression.
Targeted Transduction of Primary Human B Cells in Vivo. RAG2/
c/ female mice (Taconic) of 6–8 weeks old were given 360 rad
whole-body irradiation. On the following day, 100  106 fresh
human PBMCs (AllCells) were transferred by tail vein injection
into each mouse. After 6 h, concentrated virus (100  106 TU per
mouse) or PBS (as control) was administered via the tail vein. Two
days later, whole blood was collected from these mice via heart
puncture, and the cells were stained for human CD3 and CD20 and
then analyzed by FACS for CD3, CD20, and GFP expression. The
mice were maintained on the mixed antibiotic sulfmethoxazole and
trimethoprim oral suspension (Hi-Tech Pharmacal) in a sterile
environment in the California Institute of Technology animal
facility in accordance with institute regulations.
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